Brief: Kahr Bio Secures $22 Mln In Equity Funding
09/01/2026 12:01
Jan 9 (Reuters) - Flerie AB FLERIE.ST: FLERIE’S PORTFOLIO COMPANY KAHR BIO PRESENTS STRONG SURVIVAL DATA FROM PHASE II TRIAL WITH DSP107 AND SECURES USD 22 MILLION IN EQUITY FUNDING FUNDS TO SUPPORT PHASE IIB TRIAL OF DSP107 IN MSS-CRC Source text: ID:nMFN7kX2Mg Further company coverage: FLERIE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))